Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track XERS with free AI briefings, catalyst countdowns, and dilution alerts.

XERS · Xeris Biopharma Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$131.1M Cash on Hand
CF+ Cash Runway
Follow XERS by email Get an email when XERS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about XERS, unsubscribe in one click. Privacy

📣 What XERS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Glucagon
FDA approved Sep 2019 · Gvoke Kit
Hypoglycemia Phase 3 · NCT02656069 Completed
Novo Glucagon Insulin Hypoglycemia Phase 3 · NCT03738865 Completed
Lilly Glucagon Insulin Hypoglycemia Phase 3 · NCT03439072 Completed
Pramlintide Diabetes Mellitus, Type 1 Phase 2 · NCT04074317 Completed
Regular Insulin Diabetes Mellitus, Type 1 Phase 2 · NCT04074317 Completed
PRAM9 Diabetes Mellitus, Type 1 Phase 2 · NCT04074317 Completed
Novo Nordisk GlucaGen® Hypoglycemia Phase 2 · NCT02081001 Completed
Glugaon RTU Injection Without Insulin Pump… Hypoglycemia Phase 2 · NCT03841526 Completed
Glucagon RTU Injection With Insulin Pump… Hypoglycemia Phase 2 · NCT03841526 Completed
G-Pen Hypoglycemia Phase 2 · NCT01972152 Completed
G-Pen Mini™ (glucagon injection) Diabetes Mellitus, Type 1 Phase 2 · NCT02411578 Completed
XeriSol glucagon Type1diabetes Phase 1 · NCT03424044 Completed

Also used in these trials (approved or third-party drugs, not XERS's own candidates): Levothyroxine Sodium.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

XERS holds $131.1M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XERS files for a raise →

👥 Who Owns XERS

Insiders 4.9% Institutions (321 holders) 61.8% Public and other holders 33.3%
HolderTypeShares% of sharesAs of
John Patrick Jr Shannon
Chief Executive Officer and Chairman of · +736,739 options
Insider 2,898,933 1.59% 2026-08-01
Kevin McCulloch
President and Chief Operating Officer · +348,994 options
Insider 1,584,208 0.87% 2026-11-05
Steven Pieper
Chief Financial Officer · +207,207 options
Insider 1,346,053 0.74% 2026-11-02
Beth Hecht
Chief Legal Officer and Corporate Secret · +162,162 options
Insider 1,086,130 0.59% 2026-11-02
John Johnson
Director · +32,996 options
Insider 707,276 0.39% 2026-06-04
Anh Tu Nguyen
Chief Medical Officer · +162,162 options
Insider 402,234 0.22% 2026-02-24
Garheng Kong
Director · +32,996 options
Insider 238,337 0.13% 2026-06-04
Marla Persky
Director · +32,996 options
Insider 157,063 0.09% 2026-06-03
Barbara-jean Anne Bormann-kennedy
Director · +32,996 options
Insider 150,693 0.08% 2026-06-04
Dawn Halkuff
Director · +32,996 options
Insider 124,603 0.07% 2026-06-04
James Aloysius Brady
Director · +32,996 options
Insider 113,359 0.06% 2026-06-04
Nerissa Kreher
Director · +37,910 options
Insider 33,582 0.02% 2026-07-01

Share count 182,700,038 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full XERS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XERS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.